Jade Biosciences在被击败的收入估算后猛增,并获得了强劲的买价升级。 Jade Biosciences surged after beating earnings estimates and receiving a strong-buy upgrade.

Jade Biosciences(JBIO)在威廉·布莱尔提升为购买量强的评级后, 于星期二猛增, 交易量比平均水平高154%。 Jade Biosciences (JBIO) surged on Tuesday after an upgrade to a strong-buy rating by William Blair, with trading volume jumping 154% above average. 股价收盘时为15.05美元,高于14.43美元,第二季度收益比预期好 (0.11美元),每股收益超过0.34美元. The stock closed at $15.05, up from $14.43, following better-than-expected Q2 earnings of ($0.11) EPS, beating estimates by $0.34. 该公司是一家以皮肤炎症和慢性痒为主的临床阶段生物技术公司,市场上限为7.3768亿美元,协商一致的“Buy”评级为“Buy”,平均价格目标为25.00美元。 The company, a clinical-stage biotech focused on inflammatory skin diseases and chronic itch, has a market cap of $737.68 million and a consensus “Buy” rating with a $25.00 average price target. 其主导方案使用小分子化合物来瞄准痒和炎症路径。 Its lead programs use small-molecule compounds to target itch and inflammation pathways.